Patents by Inventor David M. Neville, Jr.
David M. Neville, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230073248Abstract: Embodiments disclosed herein relate to compositions and methods for inducing transplantation tolerance using immunomodulation agents. In certain embodiments compositions and methods disclosed herein, concern administering a composition including, but not limited to, anti-CD3 immunotoxin and administering a composition including, but not limited to, peripheral blood cells obtained from a donor of an organ, tissue or cells to be transplanted. In some embodiments, compositions and methods disclosed here can be used for modulating B- and/or T-cell-mediated immunity and/or rejection by reducing or eliminating anti-donor antibody production. Other embodiments concern modulating T-cell production in a subject preparing for, undergoing organ, tissue or cellular transplantation; or having or expected of developing GvHD for reducing the risk of, preventing or treating rejection or GvHD. In certain embodiments, combination compositions of anti-CD3 immunotoxin and peripheral blood cells from a donor are contemplated.Type: ApplicationFiled: August 18, 2022Publication date: March 9, 2023Inventors: Christene A. Huang, David M. Neville, JR., Elizabeth Anne Pomfret, Raimon Duran-Struuck, Zhirui Wang
-
Patent number: 9364557Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.Type: GrantFiled: August 1, 2008Date of Patent: June 14, 2016Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SCOTT AND WHITE HEALTHCAREInventors: David M. Neville, Jr., Jung-Hee Woo, Arthur Frankel
-
Publication number: 20150166660Abstract: Methods of modulating the immune systems of patients suffering from cancers that do not hear, or do not uniformly bear, surface CD3 are provided. The methods involve administering an anti-CD3 immunotoxin (e.g. A-dmDT390-bisFv(UCHT1)), to the patient so a to cause the patient's Immune system to recognize and destroy non-CD3 cancer cells.Type: ApplicationFiled: March 13, 2013Publication date: June 18, 2015Inventor: David M. Neville, JR.
-
Patent number: 8987426Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: April 10, 2012Date of Patent: March 24, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health & Human Services, Novartis AGInventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 8921097Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: GrantFiled: November 30, 2010Date of Patent: December 30, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: David M. Neville, Jr., Jung-Hee Woo, Yuan-Yi Liu
-
Publication number: 20130217861Abstract: The present invention relates to a method of expressing an immunotoxin in Pichia pastoris strain mutated to toxin resistance comprising a) growing the Pichia pastoris in a growth medium comprising an enzymatic digest of protein and yeast extract and maintaining a dissolved oxygen concentration at 40% and above; and b) performing methanol induction with a limited methanol feed of 0.5-0.75 ml/min/IO L of initial volume during induction along with a continuous infusion of yeast extract at a temperature below 17.5° C., antifoaming agent supplied up to 0.07%, agitation reduced to 400 RPM, and the induction phase extended out to 163 h.Type: ApplicationFiled: November 30, 2010Publication date: August 22, 2013Applicant: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: David M. Neville, JR., Jung-Hee Woo, Yuan-Yi Liu
-
Publication number: 20130211049Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be ex-pressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: April 10, 2012Publication date: August 15, 2013Applicants: Office of Technology TransferInventors: David M. Neville, JR., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 8217158Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: GrantFiled: March 5, 2010Date of Patent: July 10, 2012Assignee: The United States of America, as represented by the Secretary, Department of Health & Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Publication number: 20110189209Abstract: Provided are methods and compositions related to diphtheria toxin diabody immunotoxins.Type: ApplicationFiled: August 1, 2008Publication date: August 4, 2011Applicant: The Government of The United States of America as Represented by the Secretary, Dept. of HealthInventors: David M. Neville, JR., Jung-Hee Woo, Arthur Frankel
-
Publication number: 20110086416Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.Type: ApplicationFiled: March 5, 2010Publication date: April 14, 2011Applicant: The Government of the US, as Represented by the Secretary, Department of Health and Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 7696338Abstract: The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.Type: GrantFiled: May 18, 2001Date of Patent: April 13, 2010Assignees: The United States of America as represented by the Department of Health and Human Services, Novartis AGInventors: David M. Neville, Jr., Jerry T. Thompson, Huaizhong Hu, Jung-Hee Woo, Shenglin Ma, Jonathan Mark Hexham, Mary Ellen Digan
-
Patent number: 7517527Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.Type: GrantFiled: September 3, 1999Date of Patent: April 14, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jr., Jerry Todd Thompson, Huaizhong Hu, Shenglin Ma
-
Publication number: 20030157093Abstract: Provided is a method of treating an autoimmune disease in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the autoimmune disease is treated. In a further embodiment, the invention provides a method of treating T cell leukemias or lymphomas in an animal comprising administering to the animal an antibody-DT mutant immunotoxin which routes by the anti-CD3 pathway, or derivatives thereof, under conditions such that the T cell leukemias or lymphomas are treated.Type: ApplicationFiled: September 3, 1999Publication date: August 21, 2003Inventors: DAVID M. NEVILLE, JR., JOSHUA E. SCHARFF, JERRY TODD THOMPSON, HUAIZHONG HU, SHENGLIN MA
-
Patent number: 5762927Abstract: Disclosed is a method of inhibiting a rejection response by a primate to a transplanted organ. One exposes the primate to a mutant diphtheria toxin linked to anti-CD3 antibody so as to largely eliminate the host's peripheral blood T cell lymphocyte population. At the same time as, or after, the exposure step one administers to the primate's thymus gland donor lymphocytes. Transplantation of the organ follows. The primate is tolerized to the transplanted organ.Type: GrantFiled: April 11, 1997Date of Patent: June 9, 1998Assignees: Wisconsin Alumni Research Foundation, David M. Neville, Jr.Inventors: Stuart J. Knechtle, Jue Wang, Jon A. Wolff, David M. Neville, Jr.
-
Patent number: 5167956Abstract: The present invention relates to an immunotoxin. The invention further relates to a method of treating T cell leukemias and lymphomas, graft-versus-host diseases, and autoimmune diseases by administering an immunotoxin.Type: GrantFiled: February 11, 1991Date of Patent: December 1, 1992Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jr., Joshua E. Scharff
-
Patent number: 5066490Abstract: Crosslinking reagents for amino group-containing compounds are provided, which crosslinkers can be cleaved under mildly acidic conditions. The crosslinkers can be used to crosslink biologically active substances to be delivered to the cells, wherein the crosslinker will be cleaved in the mildly acidic conditions within the cell.Type: GrantFiled: June 1, 1988Date of Patent: November 19, 1991Assignee: The United States of America as represented by the Secretary of the Department of Health & Human ServicesInventors: David M. Neville, Jr., Kasturi Srinivasachar
-
Patent number: 4520011Abstract: The rate of protein synthesis inhibition is significantly increased by adding excess ricin B chain to target cells independent of the amount of ricin A chain bound to the cell surface membrane. Ricin is a known toxin from albumin of the castor oil bean and contains an A chain and a B chain for binding to receptors. The present invention is concerned with ricin hybrids such as OX-7-ricin A chain and 19E12-F(ab) ricin A chain which were produced by conjugation of the ricin A chains with anti-Thy 1.1 monoclonal antibodies. The conjugates were utilized in pharmaceutical amounts in mice.Type: GrantFiled: February 19, 1982Date of Patent: May 28, 1985Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jr., Richard J. Youle
-
Patent number: 4520226Abstract: A reagent and the protocol for the treatment of Graft Versus Host Disease is disclosed. Monoclonal antibodies specific for T-lymphocytes in human donor bone marrow are covalently linked to separate ricin toxin, combined in a mixture to form a treatment reagent, and combined with bone marrow removed from a human donor. The bone marrow-reagent mixture is then infused into an irradiated recipient. This protocol virtually eliminates T-lymphocyte activity, the cause of Graft Versus Host Disease.Type: GrantFiled: January 7, 1983Date of Patent: May 28, 1985Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jr., Richard J. Youle
-
Patent number: 4500637Abstract: A monoclonal antibody known as TA-1 directed against human T-cells is covalently linked to the toxin ricin and used to treat human donor bone marrow before the marrow is infused into a human recipient.Type: GrantFiled: July 19, 1982Date of Patent: February 19, 1985Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville, Jr., Richard J. Youle
-
Patent number: 4440747Abstract: The receptor specificity of toxins can be altered by coupling the intact toxin to monoclonal antibodies directed to the cell surface antigen Thy 1.2. Monoclonal antibody Thy 1.2-ricin (or ricin A chain) is a pretreatment reagent used to eliminate graft-versus-host disease (GVHD) in bone marrow transplants.Type: GrantFiled: February 19, 1982Date of Patent: April 3, 1984Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David M. Neville Jr., Richard J. Youle